Critical Limb Ischemia Treatment Market to Reach US$ 13.13 Billion by 2032 at 7.90% CAGR; North America Leads with 44% Share - Key Players: Medtronic plc, Boston Scientific Corporation, Abbott Laboratories

The global Critical Limb Ischemia (CLI) Treatment Market reached US$6.02 billion in 2024 and is expected to reach US$13.13 billion by 2032, growing at a CAGR of 7.90% during the forecast period of 2025 to 2032. The market is expanding steadily due to the increasing prevalence of peripheral artery disease (PAD) and the rising need for effective treatment solutions to prevent limb loss and improve patient outcomes.

Critical Limb Ischemia (CLI) is a severe condition characterized by significant obstruction of the arteries, leading to reduced blood flow to the extremities, particularly the legs and feet. It represents the advanced stage of peripheral artery disease, primarily caused by atherosclerosis, where fatty deposits accumulate in the arteries and restrict circulation. The condition is associated with symptoms such as ischemic rest pain, non-healing ulcers, and wounds, which can significantly impact quality of life and may lead to amputation if untreated.

Market growth is driven by the rising incidence of diabetes, cardiovascular diseases, and aging populations, all of which increase the risk of PAD and CLI. Increasing awareness regarding early diagnosis and advancements in treatment options such as endovascular procedures, angioplasty, stenting, and surgical bypass are improving clinical outcomes. In addition, technological advancements in minimally invasive therapies, growing healthcare infrastructure, and increasing healthcare expenditure are accelerating market adoption. The focus on limb preservation, improved wound care management, and ongoing research and development activities are further supporting market growth, positioning CLI treatment as a critical segment within vascular and cardiovascular care.

Download a sample PDF of this report (get higher priority for a corporate email ID): - https://www.datamintelligence.com/download-sample/critical-limb-ischemia-treatment-market?sai-v

Key Developments
✅ February 2026: Across North America, Europe, and Asia Pacific, rising prevalence of peripheral arterial disease (PAD) and diabetes significantly increased demand for advanced critical limb ischemia (CLI) treatment solutions.

✅ January 2026: Globally, rapid adoption of minimally invasive endovascular procedures such as angioplasty, stenting, and atherectomy improved patient outcomes and reduced recovery time, driving treatment adoption.

✅ December 2025: Leading companies such as Medtronic, Boston Scientific Corporation, Abbott Laboratories, Cook Medical, and Terumo Corporation strengthened their portfolios through innovations in drug-coated balloons, stents, and atherectomy systems.

✅ November 2025: Increasing focus on limb preservation and reduction of amputation rates accelerated adoption of integrated treatment approaches, including revascularization and wound care therapies.

✅ October 2025: Companies intensified investments in regenerative medicine, including stem cell and gene therapies, offering new treatment avenues for patients unresponsive to conventional therapies.

✅ September 2025: Across key regions including the United States, Germany, China, India, and Japan, improving healthcare infrastructure and rising awareness of early diagnosis supported market expansion.

Key Players
Medtronic plc | Boston Scientific Corporation | Abbott Laboratories (Cardiovascular Systems, Inc.) | Inari Medical | Koninklijke Philips N.V. | Lisata Therapeutics | Cook Medical | Baxter International Inc. | B. Braun Melsungen AG | Biotronik SE & Co. KG | Others

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=critical-limb-ischemia-treatment-market?sai-v

Market Drivers
- Rising prevalence of Peripheral Artery Disease is significantly increasing the incidence of Critical Limb Ischemia, driving demand for advanced treatment solutions.

- Growing global burden of chronic diseases such as Diabetes and hypertension is accelerating vascular complications, thereby boosting the need for CLI therapies.

- Rapidly aging population worldwide is contributing to higher risk of arterial blockages and poor circulation, increasing the patient pool for CLI treatments.

- Increasing adoption of minimally invasive endovascular procedures such as angioplasty and stenting is enhancing treatment outcomes and driving market growth.

- Rising focus on limb preservation and reduction in amputation rates is encouraging early intervention and advanced therapeutic adoption.

- Technological advancements in drug-eluting devices, imaging systems, and vascular therapies are improving clinical success rates and expanding treatment options.

- Growing awareness and early diagnosis of Critical Limb Ischemia are supporting timely treatment and improving patient outcomes.

Industry Developments

- Shift toward minimally invasive and endovascular revascularization techniques replacing traditional surgical bypass procedures.

- Increasing development of regenerative and cell-based therapies aimed at improving blood flow and tissue repair.

- Rising adoption of drug-eluting balloons, stents, and atherectomy devices for enhanced treatment efficiency and reduced re-intervention rates.

- Growing integration of advanced imaging technologies and hybrid operating rooms to improve procedural precision.

- Expansion of outpatient and ambulatory surgical centers for cost-effective and accessible CLI treatments.

- Increasing research in gene therapy and biologics to promote vascular regeneration and long-term disease management.

- Strategic collaborations between device manufacturers and healthcare providers to enhance product innovation and global reach.

Regional Insights
North America 44% share: Dominates the market due to high prevalence of vascular diseases, strong reimbursement frameworks, and advanced healthcare infrastructure.

Europe 24% share: Growth supported by increasing adoption of advanced vascular therapies and strong regulatory standards for patient safety.

Asia Pacific 22% share: Fastest-growing region driven by rising healthcare investments, growing patient population, and expanding access to vascular treatment technologies in countries such as China and India.

Latin America 6% share: Emerging growth fueled by improving healthcare infrastructure and increasing awareness of vascular diseases.

Middle East & Africa 4% share: Gradual growth driven by healthcare modernization and rising government initiatives for chronic disease management.

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/critical-limb-ischemia-treatment-market?sai-v

Key Segments
By Treatment Type
Drug class represents the dominant segment, driven by the widespread use of pharmaceutical therapies as the first line of treatment for various acute and chronic conditions. Increasing advancements in drug development, including biologics and targeted therapies, are further supporting segment growth. Devices also represent a significant segment, fueled by the rising adoption of medical devices for treatment, monitoring, and minimally invasive procedures across multiple therapeutic areas. Others represent an important segment, including combination therapies and alternative treatment approaches, contributing to comprehensive patient care.

By End-User
Hospitals and specialty clinics represent the dominant segment, as they provide advanced treatment facilities, skilled healthcare professionals, and access to a wide range of therapies and technologies. Ambulatory surgical centers (ASCs) also represent a significant segment, driven by the growing preference for outpatient procedures, cost efficiency, and reduced hospital stays. Others represent a growing segment, including homecare settings and rehabilitation centers, supported by increasing demand for decentralized and patient-centric healthcare services.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a market research and consulting firm that provides end-to-end business solutions to organizations from research to consulting. We, at DataM Intelligence, leverage our top trademark trends, insights, and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology, ensuring that our clients receive tailored insights that address their specific business challenges and objectives.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains, creating business solutions for more than 200+ companies across 50+ countries, catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.